NCT06641128View on ClinicalTrials.gov

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

March 10, 2025

Study Completion Date

April 10, 2025

Conditions
Rheumatoid Arthritis (RA)Methotrexate Induced NephrotoxicityMethotrexate Adverse Reaction
Interventions
DRUG

MTX SC or IM

IM or SC Methotrexate

DRUG

Empagliflozin 25mg tab

Empa tablets 25 mg once daily for 3 months.

Trial Locations (1)

35511

Outpatient Clinic of Internal Medicine, Rheumatology and Immunology Department, Mansoura University Hospital, Al Mansurah

All Listed Sponsors
lead

Tanta University

OTHER

NCT06641128 - The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate | Biotech Hunter | Biotech Hunter